| Rasburicase for the treatment of tumor lysis in hematological malignancies. | |
| | |
MedLine Citation:
|
PMID: 22272702 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Tumor lysis syndrome (TLS) is a common oncologic emergency in patients with hematological malignancies sensitive to cytotoxic treatment that present a high proliferative rate. High proliferative cancer rate, high sensitivity of cytotoxic treatment and renal failure represent risk factors for development of TLS. TLS is also responsible for several electrolytic alterations, such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. There are different established therapeutic options for the treatment of TLS such as hydration, allopurinol and rasburicase. Rasburicase reduces uric acid levels within 4 h, both in pediatric and adult patients, catalyzing the oxidation of uric acid into allantoin, rapidly excreted by the kidneys. Rasburicase is well tolerated and was approved in the EU and in the USA for the management of acute hyperuricemia. |
| | |
Authors:
|
Giulia Malaguarnera; Maria Giordano; Mariano Malaguarnera |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of hematology Volume: 5 ISSN: 1747-4094 ISO Abbreviation: Expert Rev Hematol Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101485942 Medline TA: Expert Rev Hematol Country: England |
Other Details:
|
Languages: eng Pagination: 27-38 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine & Systemic Pathologies, Ospedale Cannizzaro, Viale Messina, 829-95125 Catania, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Next Document: EuroThrombosis: annual meeting of the European Society of Cardiology Working Group on Thrombosis.